Bayer Ag · XETR:BAYN
Bayer — Technical Presentation (August 2026)
8 slides from Bayer's technical presentation, Aug 29, 2026
Slide 1: Real-World Effectiveness and Safety of Finerenone in Patients With CKD and Type 2 Diabetes
Real-World Effectiveness and Safety of Finerenone in Patients With CKD and Type 2 Diabetes in the United States: A FOUNTAIN Platform Analysis ESC 2026; Munich, Germany Sapna Rao (RTI Health Solutions) svrao@rti.org 29 August 2026
Slide 2: Background
Background Chronic kidney disease (CKD) and type 2 diabetes (T2D) occur together frequently and are associated with substantial cardiovascular and renal morbidity. Finerenone is an oral, selective, non-steroidal mineralocorticoid receptor antagonist (nsMRA); US FDA approval: 09 July 2021. Pivotal tr
Slide 3: Study Objectives
Study Objectives Research Objective: To evaluate the effectiveness and safety of finerenone in adults with CKD and T2D initiating finerenone compared with that in patients with CKD and T2D not using finerenone. 1 Primary objective 2 Secondary objectives 3 Exploratory objective Composite cardiovascul
Slide 4: Methods – Study Design and Setting
Methods – Study Design and Setting Study Adults in the US with CKD and T2D in the HealthVerity CKD Masterset Schematic of treated and untreated Time 0s population and data source Study period 09 Jul 2021 (finerenone approval) to 31 Mar 2025 Treatment New-user study design comparing groups finerenone
Slide 5: Select Baseline Characteristics
Select Baseline Characteristics After propensity score matching Finerenone initiators Finerenone nonusers Characteristic ASD (N = 14,287) (N = 57,148) Age, mean (SD) 66.1 (12.42) 66.1 (12.32) 0.0014 Male (%) 52.6 52.8 0.0043 eGFR, mean (SD) 55.7 (21.88) 56.2 (21.64) 0.0261 Mean uACR (SD) 775.4 (1,31
Slide 6: Main Results
Main Results Cumulative incidence of composite Forest plot of hazard ratios for all outcomes cardiovascular outcome (primary outcome) CI = confidence interval; HR = hazard ratio. Note: Cumulative incidence and hazard ratios were estimated from the matched and an inverse probability of censoring weig
Slide 7: Strengths and Limitations
Strengths and Limitations Strengths Limitations • Large real-world data set using linked claims, • Exposure misclassification: dispensed electronic medical records, and laboratory data prescription does not reflect actual patient use • New-user design • Despite use of validated algorithms, potential
Slide 8: Conclusions
Conclusions • In US adults with CKD and T2D in routine care, finerenone initiation was associated with: – Lower risk of composite cardiovascular events, primarily heart failure hospitalization – Higher risk of hyperkalemia compared with no treatment • Results from this study are consistent with thos